U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H16ClNO3
Molecular Weight 305.7567
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FENOLDOPAM

SMILES

c1cc(ccc1C2CNCCc3c2cc(c(c3Cl)O)O)O

InChI

InChIKey=TVURRHSHRRELCG-UHFFFAOYSA-N
InChI=1S/C16H16ClNO3/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21/h1-4,7,13,18-21H,5-6,8H2

HIDE SMILES / InChI

Molecular Formula C16H16ClNO3
Molecular Weight 305.7567
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Fenoldopam (marketed under the brand name Corlopam) is a drug and synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist. Fenoldopam is a rapid-acting vasodilator. It is an agonist for D1-like dopamine receptors and binds with moderate affinity to α2-adrenoceptors. It has no significant affinity for D2-like receptors, α1 and β adrenoceptors, 5HT1 and 5HT2 receptors, or muscarinic receptors. Fenoldopam is a racemic mixture with the R-isomer responsible for the biological activity. The R-isomer has approximately 250-fold higher affinity for D1-like receptors than does the S-isomer. Fenoldopam Mesylate Injection, USP is indicated for the in-hospital, short-term (up to 48 hours) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function.

CNS Activity

Curator's Comment:: Fenoldopam does not cross the blood-brain barrier

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CORLOPAM

Approved Use

Adult Patients: Fenoldopam is indicated for the in-hospital, short-term (up to 48 hours) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function. Transition to oral therapy with another agent can begin at any time after blood pressure is stable during fenoldopam infusion. Pediatric Patients: Fenoldopam is indicated for the in-hospital, short-term (up to 4 hours) reduction in blood pressure.

Launch Date

8.7497277E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
10.9 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOLDOPAM plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FED
26.5 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOLDOPAM plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
26.8 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOLDOPAM plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FED
44.7 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOLDOPAM plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.6 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOLDOPAM plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FED
2.9 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOLDOPAM plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1.5 ug/kg/min single, intravenous
Highest studied dose
Dose: 1.5 ug/kg/min
Route: intravenous
Route: single
Dose: 1.5 ug/kg/min
Sources: Page: 1-61
unhealthy, 46±3
n = 9
Health Status: unhealthy
Condition: Hypertension
Age Group: 46±3
Sex: M+F
Population Size: 9
Sources: Page: 1-61
0.8 ug/kg/min single, intravenous
Recommended
Dose: 0.8 ug/kg/min
Route: intravenous
Route: single
Dose: 0.8 ug/kg/min
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
Disc. AE: Tachycardia, Hypokalemia...
AEs leading to
discontinuation/dose reduction:
Tachycardia
Hypokalemia
Anaphylactic reaction
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Anaphylactic reaction Disc. AE
0.8 ug/kg/min single, intravenous
Recommended
Dose: 0.8 ug/kg/min
Route: intravenous
Route: single
Dose: 0.8 ug/kg/min
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
Hypokalemia Disc. AE
0.8 ug/kg/min single, intravenous
Recommended
Dose: 0.8 ug/kg/min
Route: intravenous
Route: single
Dose: 0.8 ug/kg/min
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
Tachycardia Disc. AE
0.8 ug/kg/min single, intravenous
Recommended
Dose: 0.8 ug/kg/min
Route: intravenous
Route: single
Dose: 0.8 ug/kg/min
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
PubMed

PubMed

TitleDatePubMed
Radiocontrast-induced acute renal failure: allocations and outcomes.
2001
Pathophysiology of radiocontrast nephropathy and use of fenoldopam for its prevention.
2001
Controlled hypotension in children: a critical review of available agents.
2002
Clinical review: splanchnic ischaemia.
2002 Aug
Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature.
2002 Dec
Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.
2002 Jul
The third strike.
2002 Nov
Contrast-associated nephropathy.
2002 Nov-Dec
Contrast nephropathy : an evidence-based approach to prevention.
2003
Hypertensive emergencies. Etiology and management.
2003
The role of the DA1 receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients.
2003
Improving perioperative outcomes in patients with end-stage heart failure.
2003
Contemporary strategies to preserve renal function during cardiac and vascular surgery.
2003
A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and N-acetylcysteine.
2003
Pharmacological profile of the vascular responses to dopamine in the canine external carotid circulation.
2003 Apr
Fenoldopam for renal protection in patients undergoing cardiopulmonary bypass.
2003 Aug
Pharmacologic identification of putative D1 dopamine receptors in feline kidneys.
2003 Aug
Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review.
2003 Dec
Monitoring renal oxygen supply in critically-ill patients using urinary oxygen tension.
2003 Dec
Malignant hypertension presenting as hemolysis, thrombocytopenia, and renal failure.
2003 Fall
A case series of low-dose fenoldopam in seventy cardiac surgical patients at increased risk of renal dysfunction.
2003 Feb
The International Sepsis Forum's controversies in sepsis: my initial vasopressor agent in septic shock is dopamine rather than norepinephrine.
2003 Feb
Dopamine-1 receptor stimulation impairs intestinal oxygen utilization during critical hypoperfusion.
2003 Feb
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
2003 Jan 1
Fenoldopam--but not dopamine--selectively increases gastric mucosal oxygenation in dogs.
2003 Jul
Dopamine D1 receptor-dependent inhibition of NaCl transport in the rat thick ascending limb: mechanism of action.
2003 Jul 25
Acetylcysteine and fenoldopam. Promising new approaches for preventing effects of contrast nephrotoxicity.
2003 Jun
Receptor mechanisms of prenodal lymphatic constriction by dopamine.
2003 Jun 15
Galpha12- and Galpha13-protein subunit linkage of D5 dopamine receptors in the nephron.
2003 Mar
Radiocontrast-induced nephropathy.
2003 Mar-Apr
Fenoldopam treatment improves peripheral insulin sensitivity and renal function in STZ-induced type 2 diabetic rats.
2003 May
Radiocontrast-induced nephropathy and percutaneous coronary intervention: a review of preventive measures.
2003 May
Contrast agent--associated nephrotoxicity.
2003 May-Jun
[Fenoldopam and kidney function in a case of abdominal aortic pseudoaneurysm with supra-renal clamping in an emergency protocol].
2003 Nov
The effects of intraoperative fenoldopam on renal blood flow and tubular function following suprarenal aortic cross-clamping.
2003 Nov
Clinical review: the management of hypertensive crises.
2003 Oct
Perturbation of D1 dopamine and AT1 receptor interaction in spontaneously hypertensive rats.
2003 Oct
Effects of fenoldopam on renal blood flow and its function in a canine model of rhabdomyolysis.
2003 Sep
Phlebotomy in the intensive care unit: strategies for blood conservation.
2004
In vitro effects of antihypertensive drugs on thromboxane agonist (U46619)-induced vasoconstriction in human internal mammary artery.
2004 Aug
N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity.
2004 Aug 18
American society of nephrology-36th annual meeting and renal week 2003.
2004 Jan
Optimization of intestinal mucosal oxygenation in shock: a role for medical therapy?
2004 Jan
Dopamine under alpha1-blockade, but not dopamine alone or fenoldopam, increases depressed gastric mucosal oxygenation.
2004 Jan
Prevention of radiocontrast-induced nephropathy.
2004 Jul
Periprocedural hypertension: current concepts in management for the vascular surgeon.
2004 Jul-Aug
Lessons in formulary management: the case of fenoldopam for radiographic contrast material-induced nephropathy.
2004 Jun
Dopamine D1 receptor augmentation of D3 receptor action in rat aortic or mesenteric vascular smooth muscles.
2004 Mar
Fenoldopam versus nitroprusside for the treatment of hypertensive emergency.
2004 May
Effects of short-term fenoldopam infusion on gastric mucosal blood flow in septic shock.
2004 Sep
Patents

Sample Use Guides

Adults: Initiate dosing at 0.01 to 0.3 mcg/kg/min by continuous infusion. Dosing can be increased in increments of 0.05 to 0.1 mcg/kg/minute every 15 minutes or longer until target blood pressure is reached. Dilute prior to administration Pediatrics: Initiate dosing at 0.2 mcg/kg/minute by continuous infusion and titrate dose by 0.3 to 0.5 mcg/kg/min every 20-30 minutes to a maximum dose of 0.8 mcg/kg/minute
Route of Administration: Intravenous
Incubation of freshly isolated mouse kidney slices with the selective D(1)-like receptor agonists fenoldopam (10 uM) and SKF-38393 (10 uM) for 1 h induced NaPi-IIa internalization and reduced expression of NaPi-IIa in the brush border membrane (BBM).
Substance Class Chemical
Created
by admin
on Sat Jun 26 02:49:55 UTC 2021
Edited
by admin
on Sat Jun 26 02:49:55 UTC 2021
Record UNII
INU8H2KAWG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FENOLDOPAM
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
FENOLDOPAM [MI]
Common Name English
CARLACOR
Brand Name English
FENOLDOPAM [WHO-DD]
Common Name English
FENOLDOPAM [INN]
Common Name English
FENOLDOPAM [VANDF]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66884
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
WHO-ATC C01CA19
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
NDF-RT N0000175580
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
NDF-RT N0000000117
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
WHO-VATC QC01CA19
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
Code System Code Type Description
EPA CompTox
67227-56-9
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
PRIMARY
PUBCHEM
3341
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
PRIMARY
DRUG BANK
DB00800
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
PRIMARY
RXCUI
24853
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
PRIMARY RxNorm
IUPHAR
939
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
PRIMARY
WIKIPEDIA
FENOLDOPAM
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
PRIMARY
INN
4673
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
PRIMARY
NCI_THESAURUS
C61759
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
PRIMARY
MESH
D018818
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
PRIMARY
MERCK INDEX
M5280
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
PRIMARY Merck Index
DRUG CENTRAL
1153
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
PRIMARY
LACTMED
Fenoldopam
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
PRIMARY
CAS
67227-56-9
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
PRIMARY
EVMPD
SUB07577MIG
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
PRIMARY
FDA UNII
INU8H2KAWG
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
PRIMARY
ChEMBL
CHEMBL588
Created by admin on Sat Jun 26 02:49:56 UTC 2021 , Edited by admin on Sat Jun 26 02:49:56 UTC 2021
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
BINDER->LIGAND
BINDING
ENANTIOMER -> RACEMATE
TARGET -> AGONIST
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC